Blog

It is not news that GLP-1 agonists sold by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) are surging in demand and could become one of the influential drugs ever.  That demand contributed to a shortage of the active ingredients in Lilly’s and Novo Nordisk’s drugs.  During that time, drug compounders stepped into meet the supply the brands couldn’t provide.  The FDA recently announced those drug shortages were over.  The compounders sued the FDA, the brands intervened, and the cases are proceeding on an expedited basis.  What’s the status of the cases?  And, even if the drugs are returned to the shortage list, can Novo Nordisk and Lilly resort to their patents to maintain their GLP-1 monopolies?